Hurtado-Navarro et al. show that in CMML patients with KRAS mutation, the disease is associated with a constitutive activation of the NLRP3 inflammasome and a specific cytokine signature. Treatment with recombinant IL-1R antagonist (anakinra) resulted in clinical improvement but also an impaired activation of the NLRP3 inflammasome.
All Keywords
【저자키워드】 Inflammation, Anakinra, NLRP3 inflammasome, KRAS, myelodysplastic syndromes, myeloproliferative neoplasms, CMML, IL-1 blockers, NLRP3 blockers, RAS mutations,
【저자키워드】 Inflammation, Anakinra, NLRP3 inflammasome, KRAS, myelodysplastic syndromes, myeloproliferative neoplasms, CMML, IL-1 blockers, NLRP3 blockers, RAS mutations,